Your session is about to expire
← Back to Search
Hu3F8 + GM-CSF for Osteosarcoma
Study Summary
This trial is testing an antibody and drug combo to see if it can keep cancer in remission or prevent it from coming back.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is in its second or later complete remission.My kidney function is within the normal range.It's been over 3 weeks since my last cancer treatment or major surgery.I can take care of myself but might not be able to do heavy physical work.My heart is strong enough, with good pumping ability.I've had treatments with anti-GD2 antibodies but not Hu3F8, and I don't have HAHA antibodies.My cancer has spread to other parts of my body.My cancer is in its first complete remission.I don't have trouble breathing at rest and can exercise without issues.I do not have a severe infection that is putting my life at risk.My liver tests are within the required range.I am between 1 and 40 years old.My osteosarcoma has come back, confirmed by tissue analysis.My blood cell counts are within the required range and I don't need transfusions.
- Group 1: humanized anti-GD2 antibody, hu3F8, when combined with GM-CSF
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this investigation a groundbreaking case of its kind?
"GM-CSF has been extensively researched, with the first trials sponsored by Y-mAbs Therapeutics in 2011. Following successful Phase 1 clinical testing involving 68 patients, several live studies have since followed across 8 cities and 9 countries."
Does this experiment admit geriatric individuals?
"According to the enrollment requirements, patients must be between 13 months and 40 years old. Meanwhile, there are 233 studies available for minors while 958 clinical trials pertain to seniors 65 or older."
How many subjects have been enrolled in this clinical experiment?
"Affirmative. Clinicaltrials.gov documents show that this medical study, initially posted on the 1st of July 2015, is recruiting patients currently. This clinical trial aims to enlist 46 individuals from 3 different sites."
Is there still an opportunity to join this experiment?
"Based on the data available from clinicaltrials.gov, this medical study is presently enrolling patients. The trial was made public on July 1st 2015, and its details were last updated in November 17th 2022."
What research has been conducted in relation to the use of GM-CSF?
"The initial investigation of GM-CSF took place in 2011 at Memorial Sloan Kettering Cancer Center. Thus far, 41 studies have been concluded with 7 trials ongoing as of now; many of these are hosted by medical centres situated in Houston, Texas."
What potential risks does GM-CSF pose to those who utilize it?
"This Phase 2 trial has evidence to suggest that GM-CSF is safe, resulting in an estimated score of 2 on our Power scale. Unfortunately, there is not yet any data supporting its efficacy."
Share this study with friends
Copy Link
Messenger